Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the layout results in the three major fields of peptides are gradually being enriched; 2) production capacity expansion is accelerating, and R&D investment is increasing. (Mainichi Keizai Shimbun)
国金证券4月23日发布研报称，给予圣诺生物（688117.SH）增持评级。评级理由主要包括：1）全方位多肽布局巩固先发优势，多肽三大领域布局成果逐渐丰富；2）产能扩建加速地，研发投入加大。（每日经济新闻）
Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the lay
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.